Eucrates Biomedical Acquisition - Warrants (23/10/2027) Common Stock

As of the most recent data (December 2022), EUCRW shows a common stock of $12M. That compares with $100M in the prior-year period — down 88.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, EUCRW's common stock is now $12M (was $100M) — a 88.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Eucrates Biomedical Acquisition - Warrants (23/10/2027) is outperforming or lagging.

Tracking EUCRW's common stock over time shows whether Eucrates Biomedical Acquisition - Warrants (23/10/2027) is scaling, shrinking, or reshaping that part of the business. The current reading is $12M That compares with $100M in the prior-year period — down 88.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this common stock page, Stockcircle has Eucrates Biomedical Acquisition - Warrants (23/10/2027)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect common stock (currently $12M) with ownership activity and broader fundamentals.